Calithera BioSciences - Enzyme Activators as Cancer Therapeutics


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Recent News:

Calithera Biosciences Presents Pharmacodynamic Data
on CB-839 at the 2014 American Association for Cancer
Research Annual Meeting

Calithera Biosciences to Present Data on CB-839 at the
American Association for Cancer Research Annual Meeting 2014

Calithera Biosciences Appoints William D. Waddill as CFO

Calithera Biosciences Presents Preclinical Data for CB-839 Activity and Glutaminase Inhibition in Solid and Hematologic Tumors

First patient dosed on CB-839

Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium

Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting

October 29, 2013 - Calithera Biosciences Secures $35 Million in Series D Financing



Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.


Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients.


Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.  


In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.